We are live on ! Find out more
CSBR icon

Champions Oncology

5.22 USD
-0.06
1.14%
At close Updated Sep 4, 4:00 PM EDT
1 day
-1.14%
5 days
3.98%
1 month
-4.22%
3 months
-9.38%
6 months
-13%
Year to date
-21.62%
1 year
-24.57%
5 years
-47.8%
10 years
228.3%
 

About: Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.

Employees: 214

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 33.3%
Neutral 66.7%
Negative 0%
Neutral
Accesswire
14 hours ago
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close.
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026
Neutral
Zacks Investment Research
1 month ago
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Neutral
Seeking Alpha
1 month ago
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript
Positive
MarketBeat
1 month ago
Champions Oncology Q4 Earnings Call Highlights
Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.
Champions Oncology Q4 Earnings Call Highlights
Neutral
Accesswire
1 month ago
Champions Oncology Reports Record Annual Revenue of $59 Million
Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026. Fourth Quarter and Other Financial Highlights: Record annual revenue of $59.4 million Fourth quarter revenue of $13.8 million Fourth quarter oncology services margin of 51% Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year Adjusted EBITDA income all four quarters in FY 2026 Continued investment in radiopharmaceuticals, the data platform and commercial organization Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth.
Champions Oncology Reports Record Annual Revenue of $59 Million
Positive
Zacks Investment Research
1 month ago
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Positive
Zacks Investment Research
1 month ago
2 Microcaps With Gross Margin Catalysts
CSBR and CEPL have levers in place for Gross Margin improvement.
2 Microcaps With Gross Margin Catalysts
Neutral
Zacks Investment Research
1 month ago
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
Neutral
Accesswire
1 month ago
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026
Neutral
Accesswire
4 months ago
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies.
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
Price charts implemented using Lightweight Charts™